Palvella Therapeutics Newsroom

H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsMay 1 02:34 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target

BenzingaApr 30 06:50 ET

Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics

TipRanksApr 30 06:16 ET · Ratings

Why Palvella Therapeutics, Inc. (PVLA) Is Surging in 2025

Yahoo FinanceApr 30 05:44 ET

One Palvella Therapeutics Insider Raised Their Stake In The Previous Year

Yahoo FinanceApr 26 10:28 ET

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

GlobeNewswireApr 23 16:15 ET

Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder

MT NewswiresApr 22 10:23 ET

Palvella Therapeutics: USPTO Issues Patent For Claims Related To Palvella's Product Candidate QTORIN 3.9% Rapamycin Anhydrous Gel

BenzingaApr 22 07:34 ET

Express News | Palvella Therapeutics Granted Additional U.S. Patent for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

ReutersApr 22 07:30 ET

Palvella Therapeutics Independent Chairman of the Board Acquires 1.4% More Stock

Simply Wall StApr 14 06:32 ET

Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of...

GlobeNewswireApr 11 07:30 ET

Director Makes Bold Move With Major Stock Purchase in Palvella Therapeutics!

TipRanksApr 10 22:02 ET

Insider Purchase: Director at $PVLA Buys 2,500 Shares

Quiver QuantitativeApr 10 19:15 ET

Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $50

Moomoo NewsApr 10 02:33 ET · Ratings

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

BenzingaApr 9 08:18 ET

Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target

MT NewswiresApr 9 06:35 ET · Ratings

Palvella Therapeutics, Inc.'s (NASDAQ:PVLA) Stock Price Dropped 28% Last Week; Retail Investors Would Not Be Happy

Simply Wall StApr 8 11:35 ET

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

GlobeNewswireApr 4 08:00 ET

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

GlobeNewswireApr 2 08:00 ET

H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsApr 2 02:32 ET · Ratings